NeuroICH

Infervision is a leading AI medical technology company established in 2016, focusing on improving multidisciplinary services and operations with AI. They offer cutting-edge AI products that support medical professionals in all areas, from disease screening and diagnosis to intervention and treatment, patient management, and medical research. Their solutions include InferRead CT Lung for lung nodule detection from chest CT, InferRead DR Chest for detecting chest abnormalities from chest X-rays, InferRead CT Coronary for identifying coronary artery stenosis in coronary CTA, InferRead CT Stroke for triaging hemorrhage from brain CT, InferRead CT Bone for identifying chest fractures from chest CT, and InferRead CT Pneumonia for identifying and triaging pneumonia from chest CT. Additionally, they offer InferOperate for 3D reconstruction in thoracic, liver, and urological surgeries, InferCare for patient management and image follow-up, and InferScholar as an AI-enabled medical research tool.

Deliver personalized patient care with the only histologically validated, objective, and quantitative CTA-based arterial analysis software. Utilize ground-truth histology to visualize the source of myocardial ischemia and inform heart attack and stroke risk. Heart attack and stroke are primarily caused by non-obstructive, but unstable plaque in the arteries that goes undiagnosed and untreated. Current non-invasive testing cannot visualize the biology deep inside artery walls where heart disease develops. Elucid is harnessing scientific imaging and artificial intelligence to enable quick, accurate, noninvasive diagnoses and precise treatment of cardiovascular disease to enable better patient outcomes. Assess plaque composition with histology-validated software. Quantify heart attack and stroke risk with greater accuracy. Visualize a comprehensive and objective view of arterial disease to enable personalized treatment plans before a patient ever enters the hospital.